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ABSTRACT
[Aim] The standard treatment for locally advanced cervical cancer is cisplatin-based
concurrent chemoradiotherapy (CCRT). Although the activated PI3-kinase/AKT
pathway is known to be involved in both cisplatin-resistance and radioresistance, to
date only a few studies have reported significant associations between PIK3CA gene
mutational status and outcome by CCRT in the disease. The aim of this study was to
clarify the prognostic significance of PIK3CA mutational status in cervical cancers
treated by CCRT.
[Methods] We analyzed PIK3CA mutation in 59 patients diagnosed with stages IIB
to IVA cervical carcinomas primarily treated by CCRT with weekly cisplatin at our
institution. We used formalin-fixed paraffin-embedded biopsy specimens before
treatment. Fifty-seven out of 59 patients (97%) were locally advanced cancers with
stages IIIA to IVA. Clinicopathological data and patient survival were compared
according to PIK3CA mutational status. We further performed cell viability assay
examining the effect of a PI3-kinase inhibitor copanlisib (BAY80-6946) in
combination with cisplatin on cell proliferation of CaSki cells harboring PIK3CA
mutation.
[Results] PIK3CA mutation was present in 7 out of 59 patients (12%). No significant
clinical differences were observed according to PIK3CA mutational status. Patients
with wild-type PIK3CA showed significantly improved cancer-specific survival as
compared with mutated patients (p=0.044). Subsequent survival analyses revealed
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that PIK3CA mutation was a significant prognostic factor for poor overall survival
(multivariate adjusted HR, 3.88; 95% CI, 1.28-11.78; p=0.017) and cancer-specific
survival (multivariate adjusted HR, 3.60; 95% CI, 1.19-10.95; p=0.024). Our in-vitro
study demonstrated that copanlisib in combination with cisplatin showed mild
synergistic effect on proliferation of CaSki cells compared to single-drug treatments.
[Conclusion] The current findings suggest that molecular inhibitors targeting the
PI3-kinase/AKT pathway may improve the outcome by CCRT in cervical cancers
harboring PIK3CA mutation, providing significant implications for novel treatment
strategy based on precision medicine in the disease.
11. Introduction
PHOSPHATIDYLINOSITIDE 3‐KINASE (PI3-kinase), especially class I, has a
well-established role in cancer development1. This protein is heterodimeric with a
regulatory subunit and a catalytic subunit encoded by PIK3CA gene. PIK3CA gene is
located on 3q26.3 (Figure 1) and has a major role in the PI3-kinase/AKT pathway
(Figure 2). PIK3CA gene encodes p110 protein, which contains many domains, but
the most effective are helical and kinase domains2.
Figure 1: PIK3CA gene encodes the catalytic subunit of PI3-kinase, and is located at the long
arm of chromosome 3. It contains many domains, but the most effective are helical and kinase
domains.
2P110α protein phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) at the
third position of the inositol ring, producing phosphatidylinositol-3,4,5-triphosphate
(PIP3). PIP3 is a second cellular messenger that is important for cell growth,
proliferation, survival, motility, metabolism and angiogenesis1,3. In fact, PIK3CA
mutation and genomic aberrations promote tumorigenesis through the upregulation of
the PI3-kinase/AKT axis4.
PIK3CA gene is closely related with cancer, making it an important and promising
target for cancer treatment and drug development. Mutations of the PIK3CA gene are
associated with poor prognosis in patients with different solid tumors of different
organs, but they can lead to a favorable response to PI3-kinase/AKT inhibitors5,6.
Moreover, the PI3-kinase/AKT/mTOR is the most commonly activated pathway in
human cancer, present in 30-50% of all tumors7. PIK3CA mutations and modification
Figure 2: After binding of growth factors, the tyrosine kinase receptor on cell membrane is
phosphorylated and activated. The active receptor will then turn on the PI3-kinase enzyme
attached at its bottom. PI3-kinase phosphorylates PIP2 to PIP3. PIP3 activates PDK1 enzyme
that will phosphorylate and activate AKT. The activated AKT will then regulate downstream
proteins necessary for a variety of cell functions.
3of p110α are reported to be the most frequent driver mutations in cancer8. PIK3CA
gene is the most consistent genomic aberration in cervical cancer, and is implicated in
the progression of dysplastic uterine cervical cells into invasive cancer3,9. More than
80% of mutations are located in helical or kinase domains, commonly referred to as
exon 9 and exon 203. Nowadays, cervical cancer (Table 1) is still among the leading
cancer-related death world wide10. It was reported to represent 8% of all cancer
mortality, with a very low 5-year survival11. Moreover, it is the 4th most common
cancer among women and it represents 4% of all diagnosed cancer worldwide 12.
Table 113: Staging of cervical tumors by the International Federation of Gynecology and
Obstetrics (FIGO) and TNM classification.
Marth C, et al. Ann Oncol. 2017;28(suppl_4):iv72-iv83
4CISPLATIN is one of the strongest chemotherapeutic agents. It has an anti-tumor
activity against a large number of solid tumors, such as ovary, testis, head and neck.
Cisplatin action consists of its interaction with DNA to form DNA adducts especially
intrastrand crosslink adducts. Those adducts activate several signal transduction
pathways, involving ATR, p53, and MAPK, all necessary for cellular apoptosis14
(Figure 3). Unfortunately, even though many tumors have a good response to cisplatin
at the beginning of treatment, several become cisplatin-resistant, like small cell lung
cancer or ovarian cancer. This resistance limits the clinical use of cisplatin and
increases its toxicity. In addition, tumors with cisplatin-resistance are fully cross-
resistant to platinum-based chemotherapeutic agents and also usually resistant to other
unrelated anti-tumor agents14. The administration of cisplatin results in inhibiting cell
cycle on G2/M phase and later the cells will undergo apoptosis, but before that an
upstream of events have to occur, for instance, p53-dependent functions. First,
cisplatin activates ATR kinase which phosphorylates p53. Some genes transactivated
by p53 as a result of cisplatin exposure are associated with cell cycle arrest, DNA
repair, and apoptosis, including CDK inhibitor p21. However, cisplatin resistance
arises when cells develop the ability to replicate their DNA past the adducts. The p53
protein also transactivates Mdm2 that has a negative feedback regulation decreasing
p53 activity. Additionally, other inhibitors of apoptosis may interfere with p53
activity. AKT protein, which is downstream of p110α, promotes the activation of
Mdm2 oncoprotein and its translocation into the nucleus, where Mdm2 will
downregulate p53 and instigate resistance. The cisplatin resistance may also be due to
the inactivation of pro-apoptotic protein Bad after its phosphorylation by AKT. To
increase the complexity of cisplatin resistance, the anti-apoptotic signal can be a result
of AKT-mediated phosphorylation of procaspase 9 which leads to its inactivation,
facilitating the inhibition of the caspase cascasde14.
5RADIOTHERAPY is used to treat up to 50% of cancer patients and to manage up to
40% of cured patients. Radiotherapy affects mainly the tumor micro-environment
Figure 314: An outline of pathways implicated in mediating cisplatin-induced cellular effects.
Cell death or survival will depend on the relative intensity of the signals engendered and the
crosslink between the pathways involved.
Siddik ZH. Oncogene. 2003;22(47):7265-79
6(TME). It was reported that radiotherapy has effects on hypoxia, fibrotic response and
immune activation inside the TME15. Radiation causes endothelial cell dysfunction,
by increasing their permeability, detachment from their basal membrane and their
apoptosis, leading to post-irradiation inflammation and fibrosis. Within vessels,
irradiation generates a pro-thrombotic state characterized by platelet aggregation,
microthrombus formation and increased adhesion of inflammatory cells to endothelial
cells with subsequent diapedesis into the perivascular space4. As a result of vessel
fibrosis and microthrombus, hypo-vascularization is developed, followed by tissue
necrosis. Additionally, endothelial cells within the TME are characterized by rapid
proliferation rates, contributing to their radio sensitivity. However, many tumor cells
become resistant to hypoxia. Vascular damage triggers immune response through
increased production of cytokines, inducing immune cells recruitment. After that,
tumor revascularization happens through hypoxia-inducible factor-1α (HIF-1α).
Furthermore, markers of HIF-1 hypoxia-response pathways are strongly associated
with radiotherapy failure and resistance in many cancers. To increase the tumors
vascularization, abnormal vessels are used to decrease the impact of hypoxia. VEGF
is the principal angiogenic molecule involved in the formation of abnormal vessels4.
PI3-KINASE INHIBITORS, which bind competitively to the ATP-binding pocket of
the catalytic domain, leaded to the development of pan-PI3-kinase and isoform-
specific inhibitors. The pan-PI3-kinase may be most effective but the potential toxic
side effects on glucose metabolism and immune response are not tolerated on the long
term. On the other hand, the isoform-specific inhibitors may be well tolerated but are
difficult to develop seeing the extremely conserved nature of ATP-binding pocket4.
Copanlisib (BAY80-6946) is a novel, intravenous, potent, and highly selective pan-
class I PI3-kinase inhibitor, but with preferential activity against the p110α and p110δ
isoforms (IC50 values of 0.5, 3.7, 6.4, and 0.7 nM in cell-free assays for PI3-kinase
/β/γ/δ, respectively). Copanlisib (Figure 4) has demonstrated potent anti-tumor and
pro-apoptotic activity in various tumor cell lines and xenograft models16.
7Although the current standard treatment for locally advanced cervical cancer is
cisplatin-based concurrent chemoradiotherapy (CCRT), the 5-year survival rate in
advanced cervical cancer patients is still low (30-50%). Hence, the development of
novel treatment strategy to improve outcome by CCRT is urgently required. To date
only a few studies have reported the prognostic significance of PIK3CA mutation in
cervical cancers treated by CCRT. McIntyre et al. reported that overall survival at 5
years after CCRT was significantly worse for PIK3CA mutant patients compared to
PIK3CA wild type patients (40% vs. 70%; Figure 5)6. In another study conducted by
Wang et al., patients with PIK3CA mutations had a significantly lower complete
response rate to CCRT, 52% against 86% in patients with wild-type PIK3CA (Table
2)12. Further accumulation of evidence is warranted to clarify the prognostic
significance of PIK3CA mutation for the outcome after CCRT. Hence, the aim of the
current study was to clarify the prognostic significance of PIK3CA mutational status
in cervical cancers treated by CCRT with weekly cisplatin17. Besides, we further
examined the effect of a PI3-kinase inhibitor, copanlisib, in combination with
cisplatin on the proliferation of human cervical cancer cells harboring PIK3CA
mutation.
Figure 4: Molecular targeted agent against PI3-kinase/AKT signaling
pathway.
8Figure 5: Overall survival at 5 years after CCRT was significantly worse for PIK3CA
mutant patients compared to wild type patients (40% vs. 70%)6.
Table 2: Patients with PIK3CA mutations had a significantly lower complete response
rate to CCRT than wild-type patients (52% vs. 86%)12.
McIntyre JB et al. Gynecol Oncol. 2013;128(3):409-14
Wang J, et al. Exp Mol Pathol. 2015;98(3):407-10
92- Methods
2.1 Patients and treatment :
Patients with cervical carcinomas who were primarily treated by concurrent
chemoradiotherapy with weekly cisplatin at the University of Tsukuba Hospital
between 2001 and 2015 were identified through our database, and their medical
records were retrospectively reviewed. Staging at diagnosis was performed based on
the International Federation of Gynecology and Obstetrics (FIGO) system. Patients
mostly received whole pelvic irradiation of 50Gy and brachytherapy of 24Gy
concomitant with 5 to 6 cycles of weekly administration of 40 mg/m2 cisplatin. All
samples were obtained with informed consent or opt-out procedure in accordance
with protocols approved by the Ethics Committee University of Tsukuba Hospital.
Median follow-up duration was 77 months. Follow-up data were retrieved until 2017-
6-30. Overall survival, cancer-specific survival, and progression-free survival were
defined as the time interval from initial diagnosis to death from any cause, to death
due to cervical cancer, and to disease progression or death, respectively.
2.2 DNA extraction :
All the biopsy tissue specimens were collected before treatment. Archival FFPE
biopsy tissues were used for DNA extraction. We prepared 8 to 10 slides of 5 µm
FFPE tissues, and scratched the tissues from the slides into an autoclaved tube using
sterile surgical blades. We used the blackPREP DNA Kit (GenoStaff, Tokyo, Japan)
for DNA extraction according to the manufacturer’s instructions. We measured the
DNA quality and concentration using a Nanodrop.
2.3 DNA amplification:
We performed DNA amplification targeting exons 9 and 20 of the PIK3CA gene by
PCR as described previously18. Four different sets of primers with different annealing
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temperatures were used (Table 3, Figure 6).
PCR was conducted in 40 μL reaction volumes containing 200 ng of genomic DNA,
200 μmol/L of each deoxynucleotide triphosphate, 1× PCR Buffer II (Applied
Biosystems, Foster City, CA, USA), 1.5 mmol/L MgCl2, 1 U of AmpliTaq Gold DNA
Polymerase (Applied Biosystems), and 1 μmol/L of each primer. PCR amplifications
were performed with denaturation at 95°C for 5 min, followed by 35 cycles of 94°C
for 1 min, 53°C to 59°C for 1 min, 72°C for 1 min, and final extension at 72°C for 10
min. Electrophoresis was then performed to check the size of the target sequence.
2.4 DNA isolation:
Using the PCR samples, we performed an electrophoresis on a 1.5% agarose gel.
Under UV light and after confirmation of the DNA band size, we cut and weigh the
visible band of the gel, and then isolated the DNA using a Mini Elute Gel Extraction
Table 3: PCR primers
Primer Pair Size of PCR product Annealing Temperature
(1) PIK3CA9f-PIK3CA9r2 322bp 53oC
(2) PIK3CA9f2-PIK3CA9r 224bp 59oC
(3) PIK3CA20f-PIK3CA20r3 261bp 55oC
(4) PIK3CA20f3-PIK3CA20r 318bp 55oC
Figure 6: Location of the primers on the PIK3CA gene.
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Kit (Qiagen, Valencia, CA, USA). We measured the DNA quality and concentration
using a Nanodrop.
2.5 DNA sequencing:
The isolated DNAs were submitted to Eurofins Genomics (Tokyo, Japan) for direct
sequencing. We used BioLign software (version 4.0.6.2, http://en.bio-soft.net/) to look
for the presence of mutations.
2.6 Cell viability assay:
Human cervical cancer cell line CaSki was purchased from American Type Culture
Collection (Manassas, VA, USA). We used CaSki cells for cell viability assay (Figure
10), as these cells contain heterozygous PIK3CA mutation E545K. Cisplatin was
purchased from Wako (Osaka, Japan). Copanlisib was purchased from LKT
Laboratories (St. Paul, MN, USA). The drugs were dissolved in DMSO, aliquoted,
and stored at -80℃ until use. CaSki cells were cultured in DMEM medium containing
fetal bovine serum (10%), penicillin (100 U/mL), streptomycin (100 µg/mL) and
amphotericin B (0.25 µg/mL) in a humidified atmosphere of 5% CO2 at 37℃. Cells in
the log growth phase were seeded on 96-well plates at 2,000 cells per well. Twenty-
four hours later, cells were treated with increasing doses of cisplatin (0.01-100 µM),
copanlisib (1-10,000 nM), or cisplatin plus copanlisib. Cellular proliferation was
monitored after 72 hours of treatment using a WST-1 assay as follows. WST-1
(Dojindo, Kumamoto, Japan) and 1-methoxy PMS (Dojindo) were added to the wells
and incubated for 4 hours, and then the absorbance at 450 nm was measured and
normalized relative to the absorbance of cell cultures treated with DMSO alone. The
mean and SD were obtained from independent 3 experiments.
To determine the dose effect of combination therapy, the Chou-Talalay method and
CalcuSyn software (version 2.11, Biosoft, Cambridge, UK) were used. Cisplatin was
combined with copanlisib at a constant ratio, and the interaction was quantified based
on a combination index (CI) to assess synergism (CI < 0.9), additive effect (CI=0.9-
______
12
1.0), and antagonism (CI > 1.1).
2.7 Statistical analyses:
Differences in proportions were evaluated by the Fisher’s exact test. Differences in
continuous variables were evaluated by the t-test. Kaplan-Meier survival curves were
calculated and compared using the log-rank test. The Cox proportional hazard model
was used for univariate analysis and, after adjustment for baseline characteristics and
prognostic factors (age, FIGO stage, histology, and pelvic node metastasis),
multivariate analysis.
3. RESULTS
We analyzed DNA sequences on exons 9 and 20 of the PIK3CA gene in archival
FFPE biopsy specimens before treatment by direct sequencing in 59 patients with
stages IIB to IVA cervical carcinomas treated by CCRT with weekly cisplatin.
Among those patients, 57 (97%) were locally advanced cancers with stages IIIA to
IVA. Table 4 summarizes patient characteristics17.
Table 417. Patient characteristics.
Figure 7: Cell viability assay.
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Characteristic Number (n=59)
Mean age (range) 51.3 (28-75)
FIGO stage (%)
IIB 2 (3)
IIIA 2 (3)
IIIB 52 (88)
IVA 3 (5)
Histology (%)
SCC 53 (90)
Poorly differentiated carcinoma 2 (3)
Adenocarcinoma 2 (3)
Mucinous adenocarcinoma 1 (2)
Adenosquamous carcinoma 1 (2)
Pelvic node metastasis (%)
Present 39 (66)
Absent 20 (34)
Paraaortic node metastasis (%)
Present 13 (22)
Absent 46 (78)
Response (%)
CR 44 (75)
PR 10 (17)
SD 1 (2)
PD 4 (7)
Recurrence
No 29 (49)
Yes 25 (42)
Persistent disease 5 (8)
Recurrent site
Inside the irradiated field 13 (22)
Outside the irradiated field 15 (25)
Both 2 (3)
PIK3CA mutation
Wild type 52 (88)
Mutated 7 (12)
Lachkar B, et al. Medicine (Baltimore). 2018;97(31):e11392
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We found PIK3CA mutation in 7 out of 59 patients (12%). Five (71%) of the
mutations were mapped on the helical domain, and one (14%) on the kinase domain
of the p110α protein (Table 5)17.
Table 517. Results of PIK3CA mutation analysis.
Nucleotide Amino acid Exon Domain
1 1571G>A R524K 9 Helical
2 1624G>A E542K 9 Helical
3 1624G>A E542K 9 Helical
4 1633G>A E545K 9 Helical
5 1633G>A E545K 9 Helical
6 1634A>C E545A 9 Helical
7
3073A>G
T1025A 20 Kinase
We next compared various clinicopathologic features according to PIK3CA
mutational status, finding no significant differences in any of the variables including
age, FIGO stage, histologic subtype, and response rates after CCRT (Table 6)17.
Table 617. Relationship between PIK3CA mutational status and clinicopathological variables.
Lachkar B, et al. Medicine (Baltimore). 2018;97(31):e11392
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PIK3CA
Clinicopathologic
variable
Wild type Mutated P-value
Mean age (range) 51.3 (28-75) 51.1 (29-68) 0.97
FIGO stage
IIB 1 (2%) 1 (14%)
IIIA 2 (4%) 0 (0%)
IIIB 46 (88%) 6 (86%)
IVA 3 (6%) 0 (0%) 0.43
Histology
SCC 46 (88%) 7 (100%)
Others 6 (12%) 0 (0%) 1.0
Pelvic node metastasis
Present 35 (67%) 4 (57%)
Absent 17 (33%) 3 (43%) 0.68
Paraaortic node
metastasis
Present 12 (23%) 1 (14%)
Absent 40 (77%) 6 (86%) 1.0
Response
CR/PR 47 (90%) 7 (100%)
SD/PD 5 (10%) 0 (0%) 1.0
Recurrence
No 27 (52%) 2 (29%)
Yes 20 (38%) 5 (71%)
Persistent disease 5 (10%) 0 (0%) 0.30
Recurrent site
Inside the irradiated field 12 (48%) 1 (20%)
Outside the irradiated field 11 (44%) 4 (80%)
Both 2 (8%) 0 (0%) 0.54
We subsequently compared cancer-specific survival according to various prognostic
factors including PIK3CA mutational status (Figure 8)17. Pelvic node metastasis
showed a difference without statistical significance (p=0.053; Figure 8E).
Lachkar B, et al. Medicine (Baltimore). 2018;97(31):e11392
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Interestingly, PIK3CA mutation was the only prognostic factor showing a significant
association with poor cancer-specific survival (5-year survival rate: 64% vs. 43%;
p=0.044; Figure 8 A). We also compared overall survival and progression-free
survival according to PIK3CA mutational status, but both differences were not
significant (5-year survival rate: 64% vs. 43% and 52% vs. 21%; p=0.055 and 0.29,
Figure 817: Kaplan-Meier curves for cancer-specific survival in cervical cancers treated by
CCRT. A, cases with wild-type PIK3CA (n=52) vs. mutatnt PIK3CA (n=7); B, cases with
age<60 (n=43) vs. age>60 (n=16); C, cases with FIGO stage II (n=2) vs. III (n=54) vs. IV (n=3);
D, cases with squamous cell carcinomas (n=53) vs. other histologic types (n=6); E, cases with
negative pelvic node metastasis (n=20) vs. positive pelvic node metastasis (n=39); F, cases with
negative paraaortic node metastasis (n=46) vs. positive paraaortic node metastasis (n=13).
Lachkar B, et al. Medicine (Baltimore). 2018;97(31):e11392
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respectively; Figures 9A and 9B)17.
Next we conducted univariate and multivariate analyses of PIK3CA mutation for
survival (Table 7)17. Notably, adjusted multivariate analysis demonstrated that
PIK3CA mutation was significant for poor overall survival (hazard ratio [HR], 3.9;
95% confidence interval [CI], 1.3-11.8; p=0.017; Table 7) and cancer-specific
survival (HR, 3.6; 95% CI, 1.2-11.0; p=0.024; Table 7), but not for poor progression-
free survival (HR, 2.3; 95% CI, 0.81-6.5; p=0.12; Table 7).
Figure 917: Kaplan-Meier curves in cervical cancers treated by CCRT. A, overall survival in
cases with wild-type PIK3CA (n=52) vs. mutant PIK3CA (n=7); B, progression-free survival
in cases with wild-type PIK3CA (n=52) vs. mutant PIK3CA (n=7).
Lachkar B, et al. Medicine (Baltimore). 2018;97(31):e11392
18
Table 717. Univariate and multivariate analyses of PIK3CA mutational status for survival.
Univariate Multivariate adjusted
HR 95% CI P-value HR 95% CI P-value
Progression-free survival 1.68 0.64-4.38 0.29 2.29 0.81-6.50 0.12
Overall survival 2.57 0.95-6.90 0.062 3.88 1.28-11.78 0.017
Cancer-specific survival 2.69 0.99-7.27 0.051 3.60 1.19-10.95 0.024
Finally we performed cell viability assay to examine the effect of a PI3-kinase
inhibitor copanlisib (BAY80-6946) in combination with cisplatin on cell proliferation
of CaSki cells harboring heterozygous PIK3CA mutation. We first confirmed the
mutation in CaSki cells by DNA sequencing of the cells (Figure 10).
The ratio of viable cells was further reduced by the combination treatment compared
to single-agent treatments (Figure 11).
Figure 10: Heterozygous
PIK3CA mutation E545K in
CaSki cells.
Lachkar B, et al. Medicine (Baltimore). 2018;97(31):e11392
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By treatment with copanlisib in combination with cisplatin, IC50 decreased from 7.32
μM to 6.04 μM (Table 8). From the numerical value of the calculated Combination
Index, this effect was found to be synergistic rather than additive effect (Table 9).
Table 8: IC50 of cisplatin, copanlisib, and the combination treatment in CaSki cells.
Cisplatin Copanlisib Cisplatin + Copanlisib
IC50 7.32 μM
8.80 μM
6.04 μM (Cisplatin)
0.60 μM (Copanlisib)
Figure 11: The ratio of viable cells was
reduced by the combination treatment
compared to single-agent treatments.
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Table 9: Combination index by cisplatin plus copanlisib in CaSki cells.
Combination index <0.9 0.9-1.0 1.1<
synergistic additive antagonistic
Cisplatin + Copanlisib 0.89 (IC50)
4. DISCUSSION
Our mutational analysis found PIK3CA mutations in 12% of the patients, which is
relatively lower than the results previously reported (13-36%), possibly due to
difference in quality of samples for DNA extraction, as we used archival FFPE biopsy
specimens from patients with mostly locally advanced cancers before treatment. PI3-
kinase is a heterodimer of the catalytic subunit p110α and the regulatory subunit p85α.
P110α is composed of five domains: an adapter-binding domain (ABD; residues 16-
105), a Ras-binding domain (RBD; residues 187–289), a C2 domain (residues 330-
487), a helical domain (residues 517-694), and a kinase domain (residues 797-1068).
P85α also comprises five domains: an SH3 domain, a GAP domain, an N-terminal
SH2 (nSH2) domain, an inter-SH2 domain (iSH2), and a C-terminal SH2 domain
(cSH2). All of those mutations found in our study were mapped inside the helical or
kinase domains of p110α (Table 5). E542 and E545 on the helical domain are
suggested to biochemically interact with K379 and R340 of the nSH2 of p8519,20.
Moreover, the crystal structure of p110α/p85α complex reportedly showed that E542
and E545 are located at the interface with nSH2 in close proximity to the nSH2-kinase
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domain interface, suggesting a mechanism whereby E542K and E545K mutations can
affect the enzyme activity of p110α21. T1025 was shown to be located close to the N-
terminus of the catalytic loop, and may therefore alter the enzyme activity through
changing the conformation of the catalytic loop21. Based on these structural
information, we regard that considerable translational significance lies in our
subsequent analyses on the associations between PIK3CA mutational status and
clinicopathologic data.
Our subsequent survival analyses revealed that patients with mutant PIK3CA had
significantly worse cancer-specific survival than those with wild type, and that
PIK3CA mutation was a significant prognostic factor for poor overall and cancer-
specific survival. As regards prognostic impact of PIK3CA mutation, McIntyre et al.
previously reported that PIK3CA mutational status was strongly associated with
overall survival in FIGO stage IB/II patients, but not in stage III/IVA patients
(p=0.0002 vs. 0.98)6. However, most of the patients in our study were stage III/IVA
(97%; Table 4). Likewise, Wang et al. reported that patients without genetic
alterations (mutations or amplification) of PIK3CA had a significantly higher response
rate than those with the alterations (p=0.006)12, however our study did not find any
difference in response rate (Table 6). These discrepancies among studies may be
attributed to differences in analyzed genetic alterations (including or not
amplification), constitution of histological subtypes (including or not other than SCC)
and FIGO stages, patient follow-up durations, and/or recurrence treatment strategies.
In any case, the current findings further support the significance of PIK3CA genetic
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aberrations on outcome of cervical cancers treated by CCRT.
The results of our survival analyses are suggestive of a possibility that inhibiting PI3-
kinase by molecular targeting agents may improve outcome by CCRT with cisplatin.
Regarding the effect of PI3-kinase inhibitor combined in the treatment of cervical
cancer, there have been some preclinical studies reported. Xie et al. have recently
reported that a dual PI3-kinase/mTOR inhibitor NVP-BEZ235 treatment in
combination with cisplatin or carboplatin induced a synergistic anti-tumor response in
cervical carcinoma cells in vitro21. Likewise, PI3-kinase inhibitor LY294002
reportedly radiosensitized cervical cancer cell lines in vitro22 and in vivo23.
Moreover, Arjumand et al. recently examined in vitro whether mutated PIK3CA
confers cervical cancer cells higher resistance to cisplatin and/or radiation, and
whether this phenotype is reversed by inhibiting PI3-kinase24. They reported that
CaSki cells harboring heterozygous E545K were more resistant to cisplatin/cisplatin +
radiation than HeLa or SiHa cells with wild-type PIK3CA, and that HeLa cells stably
expressing E545K were more resistant to cisplatin/cisplatin + radiation than cells with
wild-type/depleted PIK3CA. Cells expressing E545K showed constitutively activated
PI3-kinase pathway and augmented cell migration and Pictilisib (GDC-0941) PI3-
kinase inhibitor reversed these phenotypes. In our cell viability assay as well, mild
synergistic effect on cell proliferation was likewise observed by copanlisib (BAY80-
6946) treatment combined with cisplatin.
As mentioned above, PIK3CA mutation can be theoretically involved both in
radioresistance and cisplatin resistance14,25. Our next question was which mechanism
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is primarily contributing to the observed poor survival in our patients. If
radioresistance by mutated PIK3CA is the major mechanism, there should have been
more recurrences inside the irradiated fields in patients with mutant PIK3CA than in
those with wild type, but the result was reverse (20% vs. 56%; Table 6). Conversely,
there were more recurrences outside the irradiated fields in mutant than in wild type
(80% vs. 52%; Table 6), hence we presume that cisplatin resistance may be the major
mechanism for the survival impact of PIK3CA mutation. Patients with cisplatin-
resistant tumors will have more recurrences outside the irradiated fields which should
be more critical to prognosis than recurrences inside the irradiated fields, and their
recurrence therapies are mostly platinum-based chemotherapies such as paclitaxel
plus carboplatin. This can explain why wild-type group had better survival even
though they included more of persistent diseases with no response to CCRT (10% vs.
0%; Table 6) who must have responded more to platinum-based chemotherapy
because of platinum-sensitive recurrences. Indeed by contrast with cancer-specific
survival and overall survival, when we conducted adjusted multivariate analyses of
PIK3CA mutation for progression-free survival, only trends without statistical
significance was observed (Table 7), most likely reflecting prognostic impact of
PIK3CA mutation on sensitivity to recurrence therapies. These findings may suggest
that patients would benefit from PI3-kinase inhibitors combined with not only CCRT
but also with systemic chemotherapies for recurrence. Further clinical and basic
studies are required to clarify this issue.
In conclusion, we have demonstrated here that PIK3CA mutation is a significant
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prognostic factor for poor overall and cancer-specific survival in cervical cancers
treated by CCRT with weekly cisplatin. In our in-vitro study, we further found that a
PI3-kinase inhibitor copanlisib in combination with cisplatin showed a synergistic
effect on proliferation of CaSki cells harboring PIK3CA mutation. Together with the
previously published findings, the current observations further suggest that molecular
inhibitors targeting the PI3-kinase/AKT pathway may improve the outcome by
cisplatin-based CCRT in locally advanced cervical cancers harboring PIK3CA
mutation. Further basic and clinical studies are warranted to confirm our findings.
5. STUDY LIMITATIONS
We acknowledge that our study contains a couple of limitations. First, the total
sample size is small, which may have also impacted on the small number of PIK3CA
mutations found. These limit the significance of our survival analyses, and further
accumulation of evidence is necessary to confirm our observations. Secondly, only
one cell line, PIK3CA-mutated CaSki, was used in the cell viability assay. We are
next going to perform cell viability assay using other cervical cancer cell lines
including PIK3CA wild-type SiHa. Thirdly, the effect of PI3-kinase inhibitor to the
signaling pathway was not examined in the cell viability assay. Therefore, we are
going to next examine the phosphorylation of downstream proteins by western
blotting in order to confirm the inhibition of the PI3-kinase/AKT pathway by the
inhibitors.
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